Testotoxicosis: Current viewpoint

Pediatric Endocrinology Reviews

Volumn 3, Issue 2, 2005, Pages 77-86

  Reiter, Edward O ^a,c   Norjavaara, Ensio ^b  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c Baystate Children's Hospital   (United States)

Author keywords

Androgen receptor blockade; Aromatase inhibition; Gonadotropin independent precocity; Leydig cell hyperfunction; Precocious puberty

Indexed keywords

ANASTROZOLE; BICALUTAMIDE; CYPROTERONE ACETATE; KETOCONAZOLE; MEDROXYPROGESTERONE ACETATE; PRASTERONE SULFATE; SPIRONOLACTONE; TESTOLACTONE; TESTOSTERONE;

ADRENAL INSUFFICIENCY; BODY HEIGHT; BONE MATURATION; BONE SCINTISCANNING; BRAIN SCINTISCANNING; CHILD GROWTH; CLINICAL FEATURE; CLINICAL TRIAL; CUSHINGOID SYNDROME; DIFFERENTIAL DIAGNOSIS; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; ESTROGEN SYNTHESIS; GASTROINTESTINAL DISEASE; GENE MUTATION; GROWTH ACCELERATION; GROWTH HORMONE RELEASE; GROWTH RATE; GYNECOMASTIA; HORMONAL REGULATION; HORMONE ACTION; HORMONE BLOOD LEVEL; HUMAN; HYPERKALEMIA; HYPONATREMIA; LABORATORY TEST; LIVER TOXICITY; LUTEINIZING HORMONE BLOOD LEVEL; METABOLIC ACIDOSIS; MONOTHERAPY; ONSET AGE; PATHOGENESIS; PRECOCIOUS PUBERTY; PULSATILE HORMONE RELEASE; RASH; REVIEW; SEXUAL DEVELOPMENT; SHORT STATURE; SIDE EFFECT; STEROIDOGENESIS; TESTIS BIOPSY; TESTOTOXICOSIS; TREATMENT OUTCOME;

ANDROGEN ANTAGONISTS; ANILIDES; AROMATASE INHIBITORS; BODY HEIGHT; CHILD; CLINICAL TRIALS, PHASE II; HUMANS; MALE; NITRILES; POINT MUTATION; PUBERTY, PRECOCIOUS; RECEPTORS, LH; TRIAZOLES;

EID: 32244433913     PISSN: 15654753     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (86)

1. Plant TM. Puberty in Primates. In: Knobil E, Neill JD, eds. The Physiology of Reproduction. 2nd ed. New York: Raven Press, 1994:453-485
2. Kaprio J, Rimpela A, Winter T, Viken RJ, Rimpela M, Rose RJ. Common genetic influences on BMI and age at menarche. Hum Biol 1995;67:739-753
3. Eveleth PB. Population differences in growth: environmental and genetic factors. In: Falkner F, Tanner JM, eds. Human Growth. New York: Plenum Press, 1978:373-394
4. Van Wieringen JC. Secular Growth Changes. In: Falkner F, Tanner JM, eds. Human Growth. New York: Plenum Press, 1978:445-473
5. Bradshaw KD, Quigley CA. Disorders of pubertal development. In: Jameson JL, eds. Principles of molecular medicine. Totowa, NJ: Humana Press, 1998:569-580
6. Ankarberg-Lindgren C, Norjavaara E. Changes of diurnal rhythm and levels of total and free testosterone secretion from pre to late puberty in boys: testis size of 3 ml is a transition stage to puberty. Eur J Endocrinol 2004;151:747-757
7. Crofton PM, Evans AE, Wallace AM, Groome NP, Kelnar CJ. Nocturnal secretory dynamics of inhibin B and testosterone in pre- and peripubertal boys. J Clin Endocrinol Metab 2004;89:867-874
8. Mitamura R, Yano K, Suzuki N, Ito Y, Makita Y, Okuno A. Diurnal rhythms of luteinizing hormone, follicle-stimulating hormone, and testosterone secretion before the onset of male puberty. J Clin Endocrinol Metab 1999;84:29-37
9. Grumbach MM, Styne DM. Puberty: Ontogeny, Neuroendocrinology, Physiology, and Disorders. In: Larson PR, Kronenberg HM, Melmed S, Polonsky KS, eds. Williams Text Book of Endocrinology. 10 ed. Philadelphia: W.B. Saunders, 2002
10. Maynard LM, Wisemandle W, Roche AF, Chumlea WC, Guo SS, Siervogel RM. Childhood body composition in relation to body mass index. Pediatrics 2001;107:344-350
11. Siervosel RM, Maynard LM, Wisemandle WA, Roche AF, Guo SS, Chumlea WC, Towne B. Annual changes in total body fat and fat-free mass in children from 8 to 18 years in relation to changes in body mass index. The Fels Longitudinal Study. Ann N Y Acad Sci 2000;904:420-423
12. Guo SS, Chumlea WC, Roche AF, Siervosel RM. Age- and maturity-related changes in body composition during adolescence into adulthood: the Fels Longitudinal Study. Int J Obes Relat Metab Disord 1997;21:1167-1175
13. Drop SL, De Waal WJ, De Muinck Keizer-Schrama SM. Sex steroid treatment of constitutionally tall stature. Endocr Rev 1998;19:540-558
14. Tanner JM. The adolescent spurt in animals. In: Thomas CC, eds. Growth at adolesence. Oxford: Blackwell, 1962:223-239
15. Parfitt AM. Misconceptions (1): epiphyseal fusion causes cessation of growth. Bone 2002;30:337-339
16. Kakarla N, Bradshaw KD. Disorders of pubertal development: precocious puberty. Semin Reprod Med 2003;21:339-351
17. Palmert MR, Boepple PA. Variation in the timing of puberty: clinical spectrum and genetic investigation. J Clin Endocrinol Metab 2001;86:2364-2368
18. Seminara SB, Messager S, Chatzidaki EE, Thresher RR, Acierno JS, Jr., Shagoury JK, Bo-Abbas Y, Kuohung W, Schwinof KM, Hendrick AG, Zahn D, Dixon J, Kaiser UB, Slaugenhaupt SA, Gusella JF, O'Rahilly S, Carlton MB, Crowley WF, Jr., Aparicio SA, Colledge WH. The GPR54 gene as a regulator of puberty. N Engl J Med 2003;349:1614-1627
19. Messager S, Chatzidaki EE, Ma D, Hendrick AG, Zahn D, Dixon J, Thresher RR, Malinge I, Lomet D, Carlton MB, Colledge WH, Caraty A, Aparicio SA. Kisspeptin directly stimulates gonadotropin-releasing hormone release via G protein-coupled receptor 54. Proc Natl Acad Sci U S A 2005;102:1761-1766
20. Hull KL, Harvey S. GH as a co-gonadotropin: the relevance of correlative changes in GH secretion and reproductive state. J Endocrinol 2002;172:1-19
21. Blizzard RM, Martha PM, Kerrigan JR, Mauras N, Rogol AD. Changes in growth hormone (GH) secretion and in growth during puberty. J Endocrinol Invest 1989;12:65-68
22. Weissberger AJ, Ho KK. Activation of the somatotropic axis by testosterone in adult males: evidence for the role of aromatization. J Clin Endocrinol Metab 1993;76:1407-1412
23. Link K, Blizzard RM, Evans WE, Kaiser DL, Parker MW, Rogol AD. The effect of androgens on the pulsatile release and the 24-hour mean concentration of growth hormone on peripubertal males. J Clin Endocrinol Metab 1986;62:159-164
24. Vanderschueren D, Vandenput L, Boonen S, Lindberg MK, Bouillon R, Ohlsson C. Androgens and bone. Endocr Rev 2004;25:389-425
25. Foster CM, Hopwood NJ, Hassing JM, Hale PM, Mendes T, Kelch RP, Beitins IZ. Nocturnal serum growth hormone concentration is not augmented by short-term testosterone infusion in pubertal boys. Pediatr Res 1989;26:320-324
26. van der Eerden BC, Karperien M, Wit JM. Systemic and local regulation of the growth plate. Endocr Rev 2003;24:782-801
27. Smith EP, Boyd J, Frank GR, Takahashi H, Cohen RM, Specker B, Williams TC, Lubahn DB, Korach KS. Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Engl J Med 1994;331:1056-1061
28. Carani C, Qin K, Simoni M, Faustini-Fustini M, Serpente S, Boyd J, Korach KS, Simpson ER. Effect of testosterone and estradiol in a man with aromatase deficiency. N Engl J Med 1997;337:91-95
29. Morishima A, Grumbach MM, Simpson ER, Fisher C, Qin K. Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. J Clin Endocrinol Metab 1995;80:3689-3698
30. Bilezikian JP, Morishima A, Bell J, Grumbach MM. Increased bone mass as a result of estrogen therapy in a man with aromatase deficiency. N Engl J Med 1998;339:599-603
31. Largo RH, Prader A. Pubertal development in Swiss boys. Helv Paediatr Acta 1983;38:211-228
32. Sigurjonsdottir TJ, Hayles AB. Precocious puberty. A report of 96 cases. Am J Dis Child 1968;115:309-321
33. Sorgo W, Kiraly E, Homoki J, Heinze E, Teller WM, Bierich JR, Moeller H, Ranke MB, Butenandt O, Knorr D. The effects of cyproterone acetate on statural growth in children with precocious puberty. Acta Endocrinol (Copenh) 1987;115:44-56
34. Thamdrup E. Precocious sexual development: A clinical study of one hundred children. Dan Med Bull 1961;8:140-142
35. Maras A, Laucht M, Gerdes D, Wilhelm C, Lewicka S, Haack D, Malisova L, Schmidt MH. Association of testosterone and dihydrotestosterone with externalizing behavior in adolescent boys and girls. Psychoneuroendocrinology 2003;28:932-940
36. Bridges NA, Brook CGD. Disorders of puberty. In: Brook CGD, eds. Clinical Paediatric Endocrinology. 3 ed. Oxford: Blackwell, 1995:253-273
37. Oerter-Klein KE. Editorial: precocious puberty: who has it? Who should be treated? J Clin Endocrinol Metab 1999;84:411-414
38. Albano MC, Latronico AC, Arnhold IJ, Domenice S, Bloise W, Mendonca BB. Long-acting gonadotropin-releasing hormone agonists in the differential diagnosis of male precocious puberty. J Pediatr Endocrinol Metab 1997;10:499-503
39. Kawate N, Kletter GB, Wilson BE, Netzloff ML, Menon KM. Identification of constitutively activating mutation of the luteinising hormone receptor in a family with male limited gonadotrophin independent precocious puberty (testotoxicosis). J Med Genet 1995;32:553-554
40. Egli CA, Rosenthal SM, Grumbach MM, Montalvo JM, Gondos B. Pituitary gonadotropin-independent male-limited autosomal dominant sexual precocity in nine generations: familial testotoxicosis. J Pediatr 1985;106:33-40
41. Reiter EO, Brown RS, Longcope C, Beitins IZ. Male-limited familial precocious puberty in three generations. Apparent Leydig-cell autonomy and elevated glycoprotein hormone alpha subunit. N Engl J Med 1984;311:515-519
42. Furui K, Susanuma N, Tsukahara S, Asada Y, Kikkawa F, Tanaka M, Ozawa T, Tomoda Y. Identification of two point mutations in the gene coding luteinizing hormone (LH) beta-subunit, associated with immunologically anomalous LH variants. J Clin Endocrinol Metab 1994;78:107-113
43. Shenker A, Laue L, Kosugi S, Merendino JJ, Jr., Minegishi T, Cutler GB, Jr. A constitutively activating mutation of the luteinizing hormone receptor in familial male precocious puberty. Nature 1993;365:652-654
44. Rosenthal IM, Refetoff S, Rich B, Barnes RB, Sunthornthepvarakul T, Parma J, Rosenfield RL. Response to change with gonadotropin-releasing hormone agonist in a mother and her two sons with a constitutively activating mutation of the luteinizing hormone receptor-A clinical research center study. J Clin Endocrinol Metab 1996;81:3802-3806
45. Laue L, Chan WY, Hsueh AJ, Kudo M, Hsu SY, Wu SM, Blomberg L, Cutler GB, Jr. Genetic heterogeneity of constitutively activating mutations of the human luteinizing hormone receptor in familial male-limited precocious puberty. Proc Natl Acad Sci U S A 1995;92:1906-1910
46. Yano K, Hidaka A, Saji M, Polymeropoulos MH, Okuno A, Kohn LD, Cutler GB, Jr. A sporadic case of male-limited precocious puberty has the same constitutively activating point mutation in luteinizing hormone/ choriogonadotropin receptor gene as familial cases. J Clin Endocrinol Metab 1994;79:1818-1823
47. Cocco S, Meloni A, Marini MG, Cao A, Moi P. A missense (T577I) mutation in the luteinizing hormone receptor gene associated with familial male-limited precocious puberty. Hum Mutat 1996;7:164-166
48. Evans BA, Bowen DJ, Smith PJ, Clayton PE, Gregory JW. A new point mutation in the luteinising hormone receptor gene in familial and sporadic male limited precocious puberty: genotype does not always correlate with phenotype. J Med Genet 1996;33:143-147
49. Kraaij R, Post M, Kremer H, Milgrom E, Epping W, Brunner HG, Grootegoed JA, Themmen AP. A missense mutation in the second transmembrane segment of the luteinizing hormone receptor causes familial male-limited precocious puberty. J Clin Endocrinol Metab 1995;80:3168-3172
50. Yano K, Kohn LD, Saji M, Kataoka N, Okuno A, Cutler GB, Jr. A case of male-limited precocious puberty caused by a point mutation in the second transmembrane domain of the luteinizing hormone choriogonadotropin receptor gene. Biochem Biophys Res Commun 1996;220:1036-1042
51. Muller J, Gondos B, Kosugi S, Mori T, Shenker A. Severe testotoxicosis phenotype associated with Asp578 → Tyr mutation of the lutrophin/ choriogonadotrophin receptor gene. J Med Genet 1998;35:340-341
52. Latronico AC, Anasti J, Arnhold IJ, Mendonca BB, Domenice S, Albano MC, Zachman K, Wajchenberg BL, Tsigos C. A novel mutation of the luteinizing hormone receptor gene causing male gonadotropin-independent precocious puberty. J Clin Endocrinol Metab 1995;80:2490-2494
53. Gromoll J, Partsch CJ, Simoni M, Nordhoff V, Sippell WG, Nieschlag E, Saxena BB. A mutation in the first transmembrane domain of the lutropin receptor causes male precocious puberty. J Clin Endocrinol Metab 1998;83:476-480
54. Kremer H, Martens JW, van Reen M, Verhoef-Post M, Wit JM, Otten BJ, Drop SL, Delemarre-van de Waal HA, Pombo-Arias M, De Luca F, Potau N, Buckler JM, Jansen M, Parks JS, Latif HA, Moll GW, Epping W, Saggese G, Mariman EC, Themmen AP, Brunner HG. A limited repertoire of mutations of the luteinizing hormone (LH) receptor gene in familial and sporadic patients with male LH-independent precocious puberty. J Clin Endocrinol Metab 1999;84:1136-1140
55. Laue LL, Wu SM, Kudo M, Bourdony CJ, Cutler GB, Jr., Hsueh AJ, Chan WY. Compound heterozygous mutations of the luteinizing hormone receptor gene in Leydig cell hypoplasia. Mol Endocrinol 1996;10:987-997
56. Kosugi S, Van Dop C, Geffner ME, Rabl W, Carel JC, Chaussain JL, Mori T, Merendino JJ, Jr., Shenker A. Characterization of heterogeneous mutations causing constitutive activation of the luteinizing hormone receptor in familial male precocious puberty. Hum Mol Genet 1995;4:183-188
57. Yano K, Saji M, Hidaka A, Moriya N, Okuno A, Kohn LD, Cutler GB, Jr. A new constitutively activating point mutation in the luteinizing hormone/choriogonadotropin receptor gene in cases of male-limited precocious puberty. J Clin Endocrinol Metab 1995;80:1162-1168
58. Latronico AC, Shinozaki H, Guerra G, Jr., Pereira MA, Lemos Marini SH, Baptista MT, Arnhold IJ, Fanelli F, Mendonca BB, Segaloff DL. Gonadotropin-independent precocious puberty due to luteinizing hormone receptor mutations in Brazilian boys: a novel constitutively activating mutation in the first transmembrane helix. J Clin Endocrinol Metab 2000;85:4799-4805
59. Wu SM, Leschek EW, Brain C, Chan WY. A novel luteinizing hormone receptor mutation in a patient with familial male-limited precocious puberty: effect of the size of a critical amino acid on receptor activity. Mol Genet Metab 1999;66:68-73
60. Liu G, Duranteau L, Caret JC, Monroe J, Doyle DA, Shenker A. Leydig-cell tumors caused by an activating mutation of the gene encoding the luteinizing hormone receptor. N Engl J Med 1999;341:1731-1736
61. Latronico AC, Abell AN, Arnhold IJ, Liu X, Lins TS, Brito VN, Billerbeck AE, Segaloff DL, Mendonca BB. A unique constitutively activating mutation in third transmembrane helix of luteinizing hormone receptor causes sporadic male gonadotropin-independent precocious puberty. J Clin Endocrinol Metab 1998;83:2435-2440
62. Lumbroso S, Paris F, Sultan C. Activating Gsalpha mutations: analysis of 113 patients with signs of McCune-Albright syndrome - a European Collaborative Study. J Clin Endocrinol Metab 2004;89:2107-2113
63. Albright G, Butler AM, Hampton OA, Smith P. Syndrome characterized by ostetitis fibrosa disseminate, areas of pigmentation and endocrine dysfunction, with precocious puberty in females. N Engl J Med 1997;216:727-746
64. Itoh K, Nakada T, Kubota Y, Suzuki H, Ishigooka M, Izumi T. Testotoxicosis proved by immunohistochemical analysis and successfully treated with cyproterone acetate. Urol Int 1996;57:199-202
65. Latronico AC, Abell AN, Arnhold IJ, Liu X, Lins TS, Brito VN, Billerbeck AE, Segaloff DL, Mendonca BB. A unique constitutively activating mutation in third transmembrane helix of luteinizing hormone receptor causes sporadic male gonadotropin-independent precocious puberty. J Clin Endocrinol Metab 1998;83:2435-2440
66. Soriano-Guillen L, Lahlou N, Chauvet G, Roger M, Chaussain JL, Carel JC. Adult height after ketoconazole treatment in patients with familial male-limited precocious puberty. J Clin Endocrinol Metab 2005;90:147-151
67. Rosenthal SM, Grumbach MM, Kaplan SL. Gonadotropin-independent familial sexual precocity with premature Leydig and germinal cell maturation (familial testoxicosis): Effects of a potent luteinizing hormone-releasing factor agonist and medroxyprogesterone acetate therapy in four cases. J Clin Endocrinol Metab 1983;57:571-579
68. Laue L, Kenigsberg D, Pescovitz OH, Hench KD, Barnes KM, Loriaux DL, Cutler GB, Jr. Treatment of familial male precocious puberty with spironolactone and testolactone. N Engl J Med 1989;320:496-502
69. Laue L, Jones J, Barnes KM, Cutler GB, Jr. Treatment of familial male precocious puberty with spironolactone, testolactone, and deslorelin. J Clin Endocrinol Metab 1993;76:151-155
70. Leschek EW, Jones J, Barnes KM, Hill SC, Cutler GB, Jr. Six-year results of spironolactone and testolactone treatment of familial male-limited precocious puberty with addition of deslorelin after central puberty onset. J Clin Endocrinol Metab 1999;84:175-178
71. Schurmeyer T, Nieschlag E. Effect of ketoconazole and other imidazole fungicides on testosterone biosynthesis. Acta Endocrinol (Copenh) 1984;105:275-280
72. Holland FJ, Fishman L, Bailey JD, Fazekas ATA. Ketoconazole in the management of precocious puberty not responsive to LHRH-analogue therapy. N Engl J Med 1985;312:1023-1028
73. The Royal Pharmaceutical Society of Great Britain. Antifungal agents: ketoconazole. In: Reynolds JEF, eds. Martindale The Extra Pharmacopoeia. 32nd ed. London: The Pharmaceutical Press, 1999:383-384
74. Lee TC, Miller WL, Auchus RJ. Medroxyprogesterone acetate and dexamethasone are competitive inhibitors of different human steroidogenic enzymes. J Clin Endocrinol Metab 1999;84:2104-2110
75. Willemse PH, van der PE, Sleijfer DT, Tjabbes T, van Veelen H. A randomized comparison of megestrol acetate (MA) and medroxyprogesterone acetate (MPA) in patients with advanced breast cancer. Eur J Cancer 1990;26:337-343
76. Beex L, Burghouts J, van Turnhout J, Breed W, Hillen H, Holdrinet A, Boetius G, Hoogendoorn G, Doesburg W, Verhulst M. Oral versus im administration of high-dose medroxyprogesterone acetate in pretreated patients with advanced breast cancer. Cancer Treat Rep 1987;71:1151-1156
77. Learoyd D, McElduff A. Medroxyprogesterone induced Cushing's syndrome. Aust N Z J Med 1990;20:824-825
78. Barradell LB, Faulds D. Cyproterone. A review of its pharmacology and therapeutic efficacy in prostate cancer. Drugs Aging 1994;5:59-80
79. Neumann F. The antiandrogen cyproterone acetate: discovery, chemistry, basic pharmacology, clinical use and tool in basic research. Exp Clin Endocrinol 1994;102:1-32
80. Kudachadkar R, O'Regan RM. Aromatase inhibitors as adjuvant therapy for postmenopausal patients with early stage breast cancer. CA Cancer J Clin 2005;55:145-163
81. Wirth M, Tyrrell C, Delaere K, Sanchez-Chapado M, Ramon J, Wallace DM, Hetherington J, Pina F, Heyns C, Borchers T, Morris T, Armstrong J. Bicalutamide ('Casodex') 150 mg in addition to standard care in patients with nonmetastatic prostate cancer: updated results from a randomised double-blind phase III study (median follow-up 5.1 y) in the early prostate cancer programme. Prostate Cancer Prostatic Dis 2005;8:194-200
82. Iversen P, Tyrrell CJ, Kaisary AV, Anderson JB, Baert L, Tammela T, Chamberlain M, Carroll K, Gotting-Smith K, Blackledge GRP. Casodex (bicalutamide) 150-mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow-up of 4 years. Urology 1998;51:389-396
83. Iversen P, Tyrrell CJ, Kaisary AV, Anderson JB, Van Poppel H, Tammela TLJ, Chamberlain M, Carroll K, Melezinek I. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. J Urol 2000;164:1579-1582
84. Kolvenbag GJCM, Blackledge GRP, Gotting-Smith K. Bicalutamide (Casodex®) in the treatment of prostate cancer: history of clinical development. Prostate 1998;34:61-72
85. Plourde PV, Reiter EO, Jou HC, Desrochers PE, Rubin SD, Bercu BB, Diamond FB, Jr, Backeljauw PF. Safety and efficacy of anastrozole for the treatment of pubertal gynecomastia: a randomized, double-blind, placebo-controlled trial. J Clin Endocrinol Metab 2004;89:4428-4433
86. Kremer H, Mariman E, Otten BJ, Moll GW, Jr., Stoelinga GB, Wit JM, Jansen M, Drop SL, Faas B, Ropers HH. Cosegregation of missense mutations of the luteinizing hormone receptor gene with familial male-limited precocious puberty. Hum Mol Genet 1993;2:1779-1783